Results 291 to 300 of about 452,381 (401)

Glucagon‐like peptide 1 (GLP‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials

Diabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4102-4108, August 2025.
Abstract Aims The prevalence of diabetes and obesity continues to rise in women of reproductive age, with significant implications for both mother and foetus. Glucagon‐like peptide‐1 receptor agonists are effective treatments of diabetes and obesity. However, no Glucagon‐like peptide‐1 receptor agonists are currently approved for use during pregnancy ...
Claire H. Parker, Craig Slattery, Donal J. Brennan, Carel W. le Roux   +3 more
wiley   +1 more source

Therapeutic role of Crateva religiosa in diabetic nephropathy: Insights into key signaling pathways. [PDF]

PLoS One
Ali M, Irfan HM, Alamgeer, Ullah A, Abdellattif MH, Elodemi M, Zubair M, Khan A, Al-Harrasi A.   +8 more
europepmc   +1 more source

Macrovascular and microvascular complications in US Medicare enrollees with type 2 diabetes with and without atherosclerotic cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4137-4147, August 2025.
Abstract Aims To assess the incidence of macrovascular and microvascular complications in US Medicare enrollees diagnosed with T2D with and without established ASCVD. Materials and Methods We conducted a retrospective cohort study using Medicare fee‐for‐service claims data from 1 January 2006, through 31 December 2021. Baseline demographic and clinical
Tyler J. Dunn, Xi Tan, Joanna Harton, Sonia Kim, Lin Xie, Cory Gamble, Daniel Rotroff   +6 more
wiley   +1 more source

Crescentic Glomerulonephritis Possibly Caused by COVID-19 Infection. [PDF]

J Clin Med
Errabelli P, Lathiya M, Mareedu N, Herrera Hernandez LP.   +3 more
europepmc   +1 more source

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Diabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4311-4319, August 2025.
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus, J. David Smeijer, Phil Ambery, Peter J. Greasley, Emma Wijkmark, David C. Wheeler, Peter Rossing, Hiddo J. L. Heerspink   +7 more
wiley   +1 more source

Optimizing preparation of renal biopsy specimens for TEM: a time-efficient approach to rapid diagnosis of kidney diseases. [PDF]

Ren Fail
Wang G, Zhu X, Liang S, Xu F, Liang D, Zeng C.   +5 more
europepmc   +1 more source

Drug-induced nephropathies.

, 1973
H C Burry
openalex  

Monoclonal immunoglobulin measurement by mass spectrometry in patients with multiple myeloma and kidney failure: Analysis from the EuLITE trial

British Journal of Haematology, EarlyView.
Graham McIlroy, Hannah V. Giles, Amy Rollins, Gemma Malin, Libby Jones, Nicola J. Wright, Oscar Berlanga, Simon North, Mark Cook, Colin Hutchison, Nils Heyne, Katja Weisel, Jennifer Pinney, Stephen Harding, Paul Cockwell, Guy Pratt   +15 more
wiley   +1 more source

Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study

Diabetes, Obesity and Metabolism, Volume 27, Issue 8, Page 4401-4414, August 2025.
Abstract Aims This study aimed to assess the risk of urinary tract cancers (UTCs), including bladder and renal cancers, in people with type 2 diabetes (T2D) initiating empagliflozin compared with people initiating any dipeptidyl peptidase‐4 inhibitor (DPP‐4i) in the United Kingdom (UK), Sweden, and Finland.
Niklas Schmedt, Ayman Alhamdow, Giorgi Tskhvarashvili, Laura Saarelainen, Xu Qiao, Muriel Lobier, Fabian Hoti   +6 more
wiley   +1 more source

Immunoglobulin M Nephropathy: A Diagnostic Dilemma Between Minimal Change Disease and Focal Segmental Glomerulosclerosis. [PDF]

Cureus
Agrawal G, Agarwal B, Sonavane K, Shirsat P.   +3 more
europepmc   +1 more source